Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases ...

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...

Buparlisib combined with paclitaxel failed to improve overall survival vs paclitaxel alone for patients with PD-1/PD-L1–pretreated HNSCC. The combination of buparlisib and paclitaxel did not show an ...

Adding zabilugene almadenorepvec to SOC chemo and nab-paclitaxel was safe and effective in patients with metastatic pancreatic ductal adenocarcinoma. The addition of zabilugene almadenorepvec (VCN-01) ...

A preliminary analysis of patient-reported outcomes for emotional functioning (EF) in patients with solid tumors revealed ...

Adding perioperative durvalumab to neoadjuvant chemotherapy did not worsen health-related quality of life for patients with muscle-invasive bladder cancer. Michiel van der Heijden, MD, PhD, medical ...

Chemotherapy-induced myelosuppression (CIM) significantly impacts quality of life for patients with cancer and leads to ...

Patient-reported outcomes showed that health-related QOL stayed at baseline for patients with HRRM-positive mHSPC receiving a niraparib regimen. Health-related quality of life (HR-QOL) remained at ...

On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age ...

Atezolizumab Subcutaneous Data and Implementation Considerations. The subcutaneous formulation of atezolizumab (PD-L1 inhibitor) received approval approximately 1 year ago based o ...